June 20, 2014

In an effort to address opioid drug abuse, governors of five New England states convened for a summit on Monday, the National Association of Boards of Pharmacy stated.

June 20, 2014

Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.

June 18, 2014

FORT WASHINGTON, Pa. — McNeil Consumer Healthcare recently introduced a new form to the Zyrtec portfolio of allergy-relief products — an oral, dissolvable tablet. Delivering the same effective 24-hour relief, Zyrtec Dissolve Tabs contains 10 mg of citrus-flavored cetirizine that melts in the mouth.

June 18, 2014

There’s a lot happening in the allergy space right now. Chattem’s Nasacort Allergy 24HR recently hit store shelves, and in a little more than 10 weeks on the shelf the nasal corticosteroid has already generated $33.6 million in sales across total U.S. multi-outlets, according to IRI.

June 17, 2014

Lannett Co. received approval from the Food and Drug Administration for codeine sulfate tablets USP, a schedule II controlled substance, in 15 mg, 30 mg and 60 mg dosage strengths.

June 17, 2014

As the heroin and opioid epidemic spreads through communities across the United States, Sens. Carl Levin, D-Mich., and Orrin Hatch, R-Utah, will hold a forum on Wednesday to discuss opioid addiction, focusing on the use of buprenorphine to help combat opioid abuse and the obstacles that have prevented even more patients from getting buprenorphine treatment. 


June 17, 2014

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

June 11, 2014

Strativa Pharmaceutical, a division of Par Pharmaceutical Cos., announced that the Food and Drug Administration approved Nascobal, a prescription B-12 supplement administered once a week as one spray.

June 10, 2014

As many as 40% of U.S. narcotic prescriptions in 2011-2012 were written by only 5% of opioid prescribers, according to a study Express Scripts presented Monday at AcademyHealth's annual research meeting.

June 9, 2014

BioDelivery Sciences International on Monday announced that the Food and Drug Administration approved its new drug application for Bunavail (buprenorphine and naloxone) buccal film (CIII).

June 9, 2014

Mylan on Monday announced the launch of carboplatin injection, 50-mg/5-ml, in multi-dose vials. The drug is the generic version of Paraplatin injection from Bristol-Myers Squibb.

June 4, 2014

Quest Products on Wednesday announced the national launch of ProVent Rosacea Moisturizing Creme, a creme formulated to help reduce the appearance of skin conditions often associated with rosacea and other skin conditions, including skin redness, age spots, facial rashes, dry skin and sun-related damage.

June 3, 2014

Actavis last week announced that it has reached an agreement with Cephalon to settle all outstanding patent litigation associated with Actavis' generic version of Nuvigil (armodafinil tablets).

June 3, 2014

Sandoz on Tuesday announced an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride line of products, Klor-Con, and market them under the Sandoz name.

June 2, 2014

Greenstone on Tuesday announced the introduction of nadolol tablets to its generic pharmaceutical product line. The drug is available in dosage strengths of 20-mg x 100, 40-mg x 100 and 80-mg x 100.

June 2, 2014

Surrey, England-based Forme Laboratories, which specializes in menopause dermatology, has brought its Stratum C skin care line developed for peri-menopausal and menopausal skin to women in the United States.

May 30, 2014

Mission Pharmacal on Thursday announced that it has begun the promotion of Elestrin (estradiol gel) 0.06% in the United States through an agreement with Meda AB. The drug is a used as a topical hormone replacement gel to help treat hot flashes caused by menopause.

May 29, 2014

Depomed on Wednesday announced that the Food and Drug Administration has accepted for filing a new drug application from Mallinckrodt for MNK-155.

May 29, 2014

Mylan on Thursday announced that it has launched atovaquone and proguanil hydrochloride tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone tablets.

May 29, 2014

Teva Pharmaceuticals announced the introduction and availability of dexmethylphenidate hydrochloride extended-release capsules, CII, in 15 mg and 30 mg strengths.

May 28, 2014

Actavis on Tuesday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration seeking approval to market saxagliptin hydrochloride tablets, 2.5 mg and 5 mg.

May 27, 2014

The American Academy of Pediatrics on Monday reported that many pregnant and breast-feeding women in the United States may be lacking iodine in their diets, which is an essential element for their babies’ brain development, according to a new policy statement, “Iodine Deficiency, Pollutant Chemicals, and the Thyroid: New Information on an Old Problem,” published in the June 2014 issue of Pediatrics.

May 27, 2014

Aurobindo Pharma on May 15 gained approval to produce a generic version of olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths.